Numerous studies have confirmed that CXCR4 has lung protective effects in multiple experimental models of ALI/ARDS (Nassoiy et al., 2018; Hirano et al., 2018) and may be a key drug target for treating ALI (Lou et al., 2022). Here, CXCR4 is linked to acute respiratory distress syndrome.